Linked Life Data

20056300

Source:http://linkedlifedata.com/resource/pubmed/id/20056300

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-3-11
pubmed:abstractText
Invasive fungal infections are significant causes of morbidity and mortality in patients with hematological malignancies. Patients with acute myeloid leukemia and those who have undergone allogeneic hematopoietic stem cell transplantation are at especially high risk. Various fungal agents are responsible for this complication, but Aspergillus spp. and Candida spp. are the most frequently isolated micro-organisms; less commonly, infections could be caused by Zygomycetes or other rare molds or yeasts. Several new systemically-administered antifungal agents have been approved for clinical use since 2001; these agents include liposomal amphotericin B, voriconazole, caspofungin, and posaconazole, and they represent a major advance in antifungal therapy and have improved the prognosis of patients with hematological malignancies. This review focuses on therapeutic aspects of the management of fungal infections in hematological patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1532-1681
pubmed:author
pubmed:copyrightInfo
Copyright (c) 2009 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
51-61
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Current therapeutic approaches to fungal infections in immunocompromised hematological patients.
pubmed:affiliation
Istituto di Ematologia, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, Rome, Italy. lpagano@rm.unicatt.it
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't